A Phase 1b/2 open label dose escalation study of Margetuximab incombination with Pembrolizumab in patients with relapsed refrectory advanced HER2 + Gastroesophageal junction or gastric cancer.

Administered By

Awarded By

Contributors

Start/End

  • January 1, 2016 - December 31, 2020